Clariant activates Texas plant for pharmaceutical-grade PEG excipients

Clariant Health Care has activated its Clear Lake, Texas facility, the company's first U.S. site dedicated to pharmaceutical-grade PEG excipient manufacturing. The fully GMP-compliant plant is designed to serve North American and Latin American customers with shorter lead times, lower inventory costs and stronger supply continuity. Clariant is also promoting its VitiPure tiered excipient platform, including VitiPure CO 35 Superior, a premium PEG-35 castor oil for oncology injectables such as paclitaxel, ahead of CPhI Milan 2026.

Key facts

Market context

Polyethylene glycol (PEG) excipients are inactive ingredients used to dissolve, stabilize and deliver active pharmaceutical ingredients in formulations. Pharmaceutical-grade PEG and PEGylated castor oil derivatives are particularly important in injectable drugs, where purity, consistency and documented quality systems are essential. Demand is driven mainly by injectable and parenteral medicines, including oncology treatments, vaccines and certain oral, topical and other drug formulations. Because these grades must meet strict GMP requirements, qualified producers are relatively few, and drug makers often face long qualification cycles when changing suppliers. Adding regional capacity in North America and Latin America can shorten transit times and reduce the need for large safety stocks, which may ease pressure on imports from distant plants. For buyers, the main effect is greater supply choice and continuity; for competing excipient producers, it raises the bar on regional service and compliance.

Source: official release on clariant.com. Summary and context written by Market Krystal.